Three doses of the Pfizer-BioNTech COVID-19 vaccine were roughly 80 percent effective at preventing infections for children ages 6 months to 5 years old, according to trial data Pfizer released Monday.
Nearly 1,700 children received a third vaccine dose at least two months after their second as part of the trial. An analysis of immune responses to the virus in a subset of the children in the study found their vaccine-driven immune response was similar to that of the second vaccine dose among people ages 16-25.
"The study suggests that a low ... dose of our vaccine, carefully selected based on tolerability data, provides young children with a high level of protection against the recent COVID-19 strains," said BioNTech CEO and Co-Founder Dr. Ugur Sahin. That initial data was focused on a two-dose initial vaccination series, according to Pfizer. Following Monday's announcement of a third dose being effective, the two companies plan to submit the latest data to the U.S. Food and Drug Administration this week.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer 3-dose COVID vaccine 80% effective against symptomatic omicron infection for youngest children
Read more »
Pfizer covid shot 80 percent effective in young kids, early data showsThe results, along with other recent developments, signal that the long and frustrating wait for a vaccine for the youngest children, the last group to lack access, could be over within weeks.
Read more »
Pfizer Says Their COVID-19 Vaccine For Kids Under 5 Is 80% Effective Against OmicronPfizer said in preliminary findings in a subset of a clinical trial indicate that 3 doses of the vaccine are 80% effective in preventing symptomatic infection.
Read more »
Three-dose Covid-19 vaccine produces strong immune response in young children, Pfizer and BioNTech sayThree child-size doses of the Pfizer/BioNTech Covid-19 vaccine appeared to be safe and showed a strong immune response in children ages 6 months to 5 years, the companies said Monday. The vaccine makers said they will finish submitting the trial data to the US Food and Drug Administration this week.
Read more »
COVID-19 vaccine for kids under 5: Pfizer says 3 small doses offer strong protectionPfizer says it plans to give the data to U.S. regulators later this week. The 18 million tots under 5 are the only group in the U.S. not yet eligible for COVID-19 vaccination.
Read more »
3 doses of COVID vaccine are effective for kids under 5, Pfizer saysThe long-awaited findings bring the vaccine one step closer to a reality for parents of children ages 6 months to 4 years — the only group that remains ineligible for vaccination.
Read more »